1 MIN. DE LECTURA
Oct 18 (Reuters) - West Pharmaceutical Services Inc (WST.N) said Pfizer Inc's (PFE.N) decision to return marketing rights of inhaled diabetes drug Exubera to Nektar Therapeutics Inc (NKTR.O) is not expected to impact its third-quarter results and annual earnings outlook.
West Pharmaceutical sees 2007 earnings, excluding items, of $2.27 to $2.37 per share.
West Pharmaceutical's tech group is one of two companies that produce the Exubera inhalation device for Nektar, which is a partner of Pfizer. (Reporting by Sweta Singh in Bangalore)